publication . Other literature type . Article . 2007

Survival benefits from neoadjuvant chemoradiotherapy or chemotherapy in oesophageal carcinoma: a meta-analysis

Val Gebski; Bryan Burmeister; B Mark Smithers; Kerwyn Foo; John Zalcberg; John Simes;
  • Published: 01 Mar 2007
  • Publisher: Elsevier BV
Abstract
Summary Background Resectable oesophageal cancer is often treated with surgery alone or with preoperative (neoadjuvant) chemoradiotherapy or chemotherapy. We aimed to clarify the benefits of neoadjuvant chemoradiotherapy or chemotherapy versus surgery alone by a meta-analysis of randomised trial data. Methods Eligible trials were identified first from earlier published meta-analyses and systematic reviews. We also used MEDLINE, Cancerlit, and EMBASE databases to identify additional studies and published abstracts from major scientific meetings since 1980. Only randomised studies with an analysis by an intention-to-treat principle were included, and searches were...
Subjects
free text keywords: Oncology, Survival rate, Medicine, business.industry, business, Adenocarcinoma, medicine.disease, Chemoradiotherapy, Neoadjuvant therapy, medicine.medical_treatment, Survival analysis, medicine.medical_specialty, Hazard ratio, Radiation therapy, Carcinoma, Internal medicine
Powered by OpenAIRE Open Research Graph
Any information missing or wrong?Report an Issue
publication . Other literature type . Article . 2007

Survival benefits from neoadjuvant chemoradiotherapy or chemotherapy in oesophageal carcinoma: a meta-analysis

Val Gebski; Bryan Burmeister; B Mark Smithers; Kerwyn Foo; John Zalcberg; John Simes;